Satsuma stock rises as migraine therapy STS101 shows safety in phase 3 trial

Sep. 20, 2022 11:14 AM ETSatsuma Pharmaceuticals, Inc. (STSA)By: Ravikash, SA News Editor

Man waking up with headache at home

FG Trade/E+ via Getty Images

Satsuma Pharmaceuticals (NASDAQ:STSA) stock rose ~5% on Sept. 20 after the company said STS101 showed a favorable safety and tolerability profile in an ongoing phase 3 trial in patients with migraine.

STS101 is a nasal powder formulation of anti-migraine drug

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.